Acumen Pharmaceuticals Stock Revenue
| ABOS Stock | USD 1.26 0.02 1.56% |
Acumen Pharmaceuticals fundamentals help investors to digest information that contributes to Acumen Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acumen Stock. The fundamental analysis module provides a way to measure Acumen Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acumen Pharmaceuticals stock.
| Last Reported | Projected for Next Year |
Acumen | Revenue |
Acumen Pharmaceuticals Company Revenue Analysis
Acumen Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Acumen
Projected quarterly revenue analysis of Acumen Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Acumen Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Acumen Pharmaceuticals' stock price.
Acumen Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Acumen Pharmaceuticals is extremely important. It helps to project a fair market value of Acumen Stock properly, considering its historical fundamentals such as Revenue. Since Acumen Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acumen Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acumen Pharmaceuticals' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Acumen Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Acumen Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in revenue category among its peers.
Acumen Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Acumen Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acumen Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acumen Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2024-12-31 | 870.6 K | Laurion Capital Management Lp | 2024-12-31 | 867 K | Hudson Bay Capital Management Lp | 2024-12-31 | 715 K | Pathstone Holdings Llc | 2024-12-31 | 606.8 K | State Street Corp | 2024-12-31 | 525.8 K | Two Sigma Advisers, Llc | 2024-12-31 | 499.1 K | Northern Trust Corp | 2024-12-31 | 307.6 K | Two Sigma Investments Llc | 2024-12-31 | 301.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 266.2 K | Ra Capital Management, Llc | 2024-12-31 | 14.9 M | Sands Capital Ventures, Llc | 2024-12-31 | 3.4 M |
Acumen Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | (94.97 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Shares Owned By Insiders | 11.23 % | ||||
| Shares Owned By Institutions | 76.56 % | ||||
| Number Of Shares Shorted | 1.74 M | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (43.56 M) | ||||
| EBITDA | (51.61 M) | ||||
| Net Income | (52.37 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 28.49 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (43.06 M) | ||||
| Short Ratio | 7.51 X | ||||
| Earnings Per Share | (1.38) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 10.8 | ||||
| Number Of Employees | 51 | ||||
| Beta | 0.024 | ||||
| Market Capitalization | 76.9 M | ||||
| Total Asset | 310.12 M | ||||
| Retained Earnings | (222.8 M) | ||||
| Working Capital | 233.64 M | ||||
| Net Asset | 310.12 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.